Current Clinical Trials
All Clinical Trials
Biliary Tract Cancer Clinical Trials
Biliary Tract
NAME: PanTumor3- Biliary Tree
What type of cancer is this for: Liver, gallbladder, bile ducts
Phase: II
Who is this trial for: Men and women who have cancer in their biliary tract: liver and/or gallbladder and/or bile ducts that has spread to other parts of the body and cannot be taken out.
What biomarkers are involved? Your cancer cells must be positive for Trop2
What is National Clinical Trial #? NCT05489211
Brief summary of trial: This trial is looking to see how well the study drug (Dato-DXd) works on biliary tract cancers that have spread, as well as how safe the drug is.
Need to know: You need to have tried either Gemzar & Carboplatin OR Gemzar & Cisplatin in the past.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Bladder Cancer Clinical Trials
Breast Cancer Clinical Trials
Breast
Name of this trial: ELAINE 3
What type of cancer is this for? BREAST
Phase of this trial: Phase III
Who is this trial for? Men and Women with Breast Cancer that has spread to other parts of the body.
What biomarkers are involved? You must have estrogen receptor positive, HER2 negative Breast Cancer with an ESR1 Mutation
What is National Clinical Trial #? NCT05696626
Brief summary of trial: This trial compares how effective and safe the combination of Lasofoxifene and Abemaciclib is, compared to the combination of Fulvestrant and Abemaciclib. Lasofoxifene and Abemaciclib are both pills, and Fulvestrant is an injection.
Need to know: You must have tried Ribociclib or palbociclib-based treatment before.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name: SERENA 6
What type of cancer is this for? BREAST
Phase: III
Who is this trial for? Men and women with Breast Cancer that has spread to other parts of the body.
What biomarkers are involved? You must be hormone receptor (HR) positive, HER2 negative and have a positive ESR1 mutation
What is National Clinical Trial #? NCT04964934
Brief summary of trial: This trial looks to see how well AZD9833 (the drug that is being studied) plus palbociclib or abemaciclib works compared to either anastrozole or letrozole plus palbociclib or abemaciclib.
Need to know: You must have tried either anastrozole or letrozole plus a CDK4/6 inhibitor (Abemaciclib, Palbociclib or Ribociclib)
Where is this trial available?: The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial? BEGONIA
What type of cancer is this for? BREAST
Phase of this trial? Phase II
Who is this trial for? Men and Women with breast Cancer that has spread to other parts of the body.
What biomarkers are involved? You must have estrogen receptor negative, progesterone receptor negative and HER2 negative breast cancer.
What is the National Clinical Trial #? NCT03742102
Brief summary of trial: This trial is looking to see how safe and well-tolerated Durvalumab and datopotamab deruxtecan are.
Need to know: You can have had treatment for your breast cancer before it spread, but now that it has spread, this has to be the first treatment you receive for it.
Where is this trial available?: The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial: GILEAD ASCENT-05
What type of cancer is this for? BREAST Cancer Triple Negative
Phase of this trial: Phase III
Who is this trial for? Men and Women with Breast Cancer early stage not cured with chemotherapy and surgery.
What biomarkers are involved? You must have estrogen receptor negative, progesterone receptor negative, and HER2 negative Breast Cancer
What is National Clinical Trial #? NCT05633654
Brief summary of trial: This trial compares how effective and safe the combination of Sacituzumab Govitecan and Pembrolizumab is, compared to treatment of physician’s choice in patients with triple negative breast cancer who have residual invasive disease after surgery and neoadjuvant therapy.
Need to know: Must have had neoadjuvant treatment and surgery for breast surgery with residual disease.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Colorectal Cancer Clinical Trials
Colorectal
Esophageal Cancer Clinical Trials
Esophageal
NAME: GEMINI GASTRIC
What type of cancer is this for? Stomach and where the stomach and esophagus join together
Phase: II
Who is this trial for: Men and women who have stomach cancer, or cancer where the stomach and esophagus meet, that cannot be removed or has spread to other parts of the body
What biomarkers are involved? Your tumor CANNOT be positive for HER-2.
What is National Clinical Trial #? NCT05702229
Brief summary of trial: This trial is looking to see how well two new drugs (MEDI5752 and AZD2936) work with chemotherapy plans that already exist.
Need to know: This must be the first treatment you receive since finding out your cancer has spread.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Gallbladder Cancer Clinical Trials
Gallbladder
NAME: PanTumor3- Biliary Tree
What type of cancer is this for: Liver, gallbladder, bile ducts
Phase: II
Who is this trial for: Men and women who have cancer in their biliary tract: liver and/or gallbladder and/or bile ducts that has spread to other parts of the body and cannot be taken out.
What biomarkers are involved? Your cancer cells must be positive for Trop2
What is National Clinical Trial #? NCT05489211
Brief summary of trial: This trial is looking to see how well the study drug (Dato-DXd) works on biliary tract cancers that have spread, as well as how safe the drug is.
Need to know: You need to have tried either Gemzar & Carboplatin OR Gemzar & Cisplatin in the past.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Gastric Cancer Clinical Trials
Gastric
NAME: GEMINI GASTRIC
What type of cancer is this for? Stomach and where the stomach and esophagus join together
Phase: II
Who is this trial for: Men and women who have stomach cancer, or cancer where the stomach and esophagus meet, that cannot be removed or has spread to other parts of the body
What biomarkers are involved? Your tumor CANNOT be positive for HER-2.
What is National Clinical Trial #? NCT05702229
Brief summary of trial: This trial is looking to see how well two new drugs (MEDI5752 and AZD2936) work with chemotherapy plans that already exist.
Need to know: This must be the first treatment you receive since finding out your cancer has spread.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Kidney Cancer Clinical Trials
Kidney
Leukemia Clinical Trials
Liver Cancer Clinical Trials
Liver
NAME: PanTumor3- Biliary Tree
What type of cancer is this for: Liver, gallbladder, bile ducts
Phase: II
Who is this trial for: Men and women who have cancer in their biliary tract: liver and/or gallbladder and/or bile ducts that has spread to other parts of the body and cannot be taken out.
What biomarkers are involved? Your cancer cells must be positive for Trop2
What is National Clinical Trial #? NCT05489211
Brief summary of trial: This trial is looking to see how well the study drug (Dato-DXd) works on biliary tract cancers that have spread, as well as how safe the drug is.
Need to know: You need to have tried either Gemzar & Carboplatin OR Gemzar & Cisplatin in the past.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Lung Cancer Clinical Trials
Lung
NAME: Carmen-LC03
What type of cancer is this for? Non-small-cell lung cancer
Phase: III
Who is this trial for? Men and women with non-squamous, non-small-cell lung cancer who have had treatment (chemo) before.
What biomarkers are involved? Your tumors must be CEACAM5 positive.
What is National Clinical Trial#? NCT04154956
Brief summary of trial: This trial is looking at which drug works best to keep your disease from growing for the longest period of time.
Need to know: You must have received either Cisplatin or Carboplatin chemotherapy and an “immune checkpoint inhibitor” in your past treatments.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name: GENMAB
What type of cancer is this for? Non-small-cell lung cancer
Phase: II
Who is this trial for? Men and women who have non-small-cell lung cancer that has spread to other parts of their body.
What biomarkers are involved? Your tumor must have PD-L1 expression in greater than 1% of your tumor cells.
What is National Clinical Trial #? NCT05117242
Brief summary of trial: This study compares how well their new drug works (shrinks the tumors) by itself vs. giving it with “pembrolizumab”.
Need to know: You need to have had the standard treatment (chemo) and an “immune checkpoint inhibitor” as prior treatment.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name: IMFORTE
What type of cancer is this for? Small-cell lung cancer
Phase: III
Who is this trial for? Men and women with extensive stage small cell lung cancer who have had a specific chemo plan before.
What biomarkers are involved? None
What is National Clinical Trial #? NCT05091567
Brief summary of trial: This trial is looking at whether Lurbinectedin works better alone, or if it works better when you add Atezolizumab.
Need to know: You need to have had four cycles of a certain chemotherapy plan: Carboplatin, Etoposide and Atezolizumab
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name: Pacific-9
What kind of cancer is this for? Non-small cell lung cancer
Phase: III
Who is this trial for? Men and women with locally advanced (Stage III) non-small cell lung cancer that cannot be removed by a doctor.
What biomarkers are involved? PD-L1, EGFR and ALK
What is National Clinical Trial #? NCT05221840
Brief summary of trial: This study is looking to prove that durvalumab and oleclumab work better than durvalumab and a placebo (harmless medication) do.
Need to know: You must have had a chemo plan that included either Cisplatin or Carboplatin, along with radiation at the same time you were getting chemotherapy. Your disease cannot have grown any bigger since chemo and radiation finished.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Lymphoma Clinical Trials
Lymphoma
NAME: ACERTA ESCALADE
What kind of cancer is this for? Diffuse Large B-Cell lymphoma.
Phase: III
Who is this trial for? Men and women who are younger than or equal to 75 years old with lymphoma that has never been treated before.
What biomarkers are involved? None
What is National Clinical Trial #? NCT04529772
Brief summary of trial: This trial is looking to see if the study drug (acalabrutinib) added to RCHOP (chemo plan) works better than RCHOP and a harmless drug.
Need to know: You must be younger or equal to 75 years old and your cancer cell type must be non-germinal center B-cell lymphoma.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial: Olympia-2, R1979-ONC-2075
What type of cancer is this trial for? Untreated Follicular Lymphoma
Trial Phase: 3
Who is this trial for? This trial is for newly diagnosed or untreated patients with Follicular Lymphoma.
What biomarkers are required for eligibility? CD20+ Follicular Lymphoma
National Clinical Trial #? NCT06097364
Brief Summary of the trial: This trial is looking at how well a new drug Odronextamb combined with Chemotherapy works, and the safety of drug compared to Rituximab (already approved treatment)and Chemotherapy for follicular lymphoma.
Need to know: Must have not had any previous treatment for follicular lymphoma.
Where is this trial available? The Cancer and Hematology Centers and other various sites across the country. Please click on link above for more information.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Melanoma Clinical Trials
Melanoma
NAME: IDE196-009
What kind of cancer is this for? Uveal melanoma
Phase: II
Who is this trial for? Men and women with primary uveal melanoma that requires either removal of the eye or radiation therapy.
What biomarkers are involved? None
What is National Clinical Trial #? NCT05907954
Brief summary of trial: This study is looking to see how people feel while they are taking the study drug, as well as how safe it is.
Need to know: The study drug is a pill, and you will have many eye exams during the trial.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
NAME: IDE196-002
What kind of cancer is this for? Metastatic Uveal melanoma
Phase: II/III
Who is this trial for? Men and women with uveal melanoma that has spread to other parts of their body.
What biomarkers are involved? None
What is National Clinical Trial #? NCT05987332
Brief summary of trial: This study is looking at how well the study drug (IDE196) plus crizotinib works, as well as how you feel when taking it.
Need to know: Your serotype must be HLA-A*02:01 negative.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Multiple Myeloma Clinical Trials
Multiple Myeloma
Name: COBRA
What kind of cancer is this for: Multiple Myeloma
Phase: III
Who is this trial for? Men and women who have just found out that they have multiple myeloma
What biomarkers are involved? None
What is National Clinical Trial#? NCT03729804
Brief summary of trial: This trial is looking at which treatment plan works better at 12 and 24 months after starting.
Need to know: Both transplant and non-transplant candidates are eligible. Transplant candidates must agree at the time of consent to defer transplant to the end of study treatment.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Myelodysplastic Syndrome Clinical Trials
Multiple Myeloma
Name: COBRA
What kind of cancer is this for: Multiple Myeloma
Phase: III
Who is this trial for? Men and women who have just found out that they have multiple myeloma
What biomarkers are involved? None
What is National Clinical Trial#? NCT03729804
Brief summary of trial: This trial is looking at which treatment plan works better at 12 and 24 months after starting.
Need to know: Both transplant and non-transplant candidates are eligible. Transplant candidates must agree at the time of consent to defer transplant to the end of study treatment.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Myelofibrosis Clinical Trials
Pancreatic Cancer Clinical Trials
Pancreas
Prostate Cancer Clinical Trials
Prostate
Name: CAPITELLO-281
What type of cancer is this for? Prostate
Phase: III
Who is this trial for? Men who have hormone sensitive prostate cancer (testosterone can be stopped or blocked to help prevent cancer growth) that has spread to other parts of the body.
What is National Clinical Trial #? : NCT04493853
Brief summary of trial: This trial is looking to see how well capivasertib and abiraterone work compared to a harmless medicine and abiraterone.
Need to know: Your tumor tissue must be PTEN negative. (PTEN stands for Phosphatase and TENsin homolog deleted on chromosome 10)
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
NAME: PanTumor 3- PROSTATE
What type of cancer is this for? Prostate
Phase: II
Who is this trial for? Men with advanced prostate cancer that may have spread to other parts of your body.
What biomarkers are involved? None
What is National Clinical Trial #? NCT05489211
Brief summary of trial: This trial is looking to see what drug combination works better to treat your prostate cancer.
Need to know: Your prostate cancer must be “castration-resistant”, which means that your cancer continues to grow even when your testosterone level is very low.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Registry Trials
Registry Trial
NAME: EXACT- Registry trial
What kind of cancer is this for? All cancer types
Phase: N/A
Who is this trial for? Men and women who either have a diagnosis of cancer, a clinical suspicion of cancer, a diagnosis of recurrent cancer or a clinical suspicion of recurrent cancer.
What biomarkers are involved? Multiple
What is National Clinical Trial #?
Brief summary of trial: This study is looking at tissue and blood samples from cancer patients, to study the biomarkers they find in the blood or tissue to help and come up with future therapies.
Need to know: There are no medications in this trial, you would need to give a blood or tissue sample for the sponsor to evaluate.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
NAME: Oracle- Registry trial
What kind of cancer is this for? All types
Phase: N/A
Who is this trial for? The primary study population will include participants with invasive bladder, ureteral, or renal pelvis carcinoma, non-small cell lung cancer, and breast cancer. Exploratory cohorts include participants with cutaneous melanoma, esophageal carcinoma, gastroesophageal junction carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, squamous cell carcinoma of the head and neck, epithelial ovarian/Fallopian tube carcinoma, endometrial cancer, renal cell carcinoma (RCC), and rectal adenocarcinoma.
What biomarkers are involved? None
What is National Clinical Trial #? NCT05059444
Brief summary of trial: This study wants to test an assay that they have developed, which could help detect recurrence in people with certain tumors.
Need to know: There are no medications on this trial, just blood draws and tissue samples are needed.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com